TDOC
VENTE TOTALE: 18 327 titres (~115 478,43 $ US)
- Insiders
- DIVITA CHARLES III
- Total bought
- —
- Total sold
- $115,478
- Last activity
- 2026-09-02
- Last synced
-
2026-09-08 09:54:45
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-04
TDOC shows genuine operational progress with improving EBITDA and debt reduction, but a weak catalyst score of 25 with no meaningful positive event driver severely limits near-term upside potential.
The first sentence of the analysis written for TDOC on 2026-09-04 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 69.5% | 70.8% | 70.8% | 69.1% | 68.0% | |
| Ebit Margin | -8.5% | -8.1% | -8.1% | -9.0% | -11.8% | |
| Ebitda Margin | 5.8% | 1.2% | 1.7% | -0.3% | -1.5% | |
| Operating Profit Margin | -10.4% | -39.7% | -9.6% | -567.3% | -13.1% | |
| Pretax Profit Margin | -9.3% | -38.7% | -8.4% | -567.7% | -18.9% | |
| Continuous Operations Profit Margin | -7.9% | -39.0% | -8.5% | -567.5% | -21.1% | |
| Net Profit Margin | -7.9% | -39.0% | -8.5% | -567.5% | -21.1% | |
| Bottom Line Profit Margin | -7.9% | -39.0% | -8.5% | -567.5% | -21.1% | |
| Current Ratio | 2.686 | 1.767 | 3.540 | 3.215 | 3.702 | |
| Quick Ratio | 2.592 | 1.727 | 3.470 | 3.075 | 3.481 | |
| Solvency Ratio | 0.095 | -0.376 | 0.016 | -5.620 | -0.131 | |
| Cash Ratio | 1.930 | 1.379 | 2.671 | 2.297 | 2.699 | |
| Price To Earnings Ratio | -6.140 | -1.549 | -15.846 | -0.280 | -33.634 | |
| Price To Earnings Growth Ratio | 0.076 | -0.005 | 0.161 | -0.000 | 0.685 | |
| Forward Price To Earnings Growth Ratio | 0.076 | -0.005 | 0.161 | -0.000 | 0.685 | |
| Price To Earnings Diluted Ratio | -6.140 | -1.549 | -16.082 | -0.280 | -33.634 | |
| Price To Earnings Diluted Growth Ratio | 0.076 | -0.005 | 0.163 | -0.000 | 0.685 | |
| Price To Book Ratio | 0.890 | 1.040 | 1.502 | 1.655 | 0.898 | |
| Price To Sales Ratio | 0.488 | 0.603 | 1.343 | 1.587 | 7.089 | |
| Price To Free Cash Flow Ratio | 4.321 | 5.481 | 18.045 | 22.096 | 77.701 | |
| Price To Operating Cash Flow Ratio | 4.191 | 5.279 | 9.984 | 20.172 | 74.283 | |
| Debt To Assets Ratio | 0.335 | 0.451 | 0.363 | 0.338 | 0.072 | |
| Debt To Equity Ratio | 0.751 | 1.063 | 0.685 | 0.688 | 0.080 | |
| Debt To Capital Ratio | 0.429 | 0.515 | 0.406 | 0.407 | 0.074 | |
| Long Term Debt To Capital Ratio | 0.418 | 0.399 | 0.398 | 0.399 | 0.071 | |
| Financial Leverage Ratio | 2.238 | 2.358 | 1.888 | 2.037 | 1.105 | |
| Working Capital Turnover Ratio | 3.602 | 2.870 | 2.664 | 2.704 | 2.507 | |
| Operating Cash Flow Ratio | 0.727 | 0.312 | 0.832 | 0.474 | 0.586 | |
| Operating Cash Flow Sales Ratio | 0.116 | 0.114 | 0.134 | 0.079 | 0.095 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.970 | 0.963 | 0.553 | 0.913 | 0.956 | |
| Debt Service Coverage Ratio | 5.935 | 0.042 | 1.923 | -0.105 | -0.931 | |
| Interest Coverage Ratio | -13.338 | -42.889 | -11.155 | -622.184 | -3.274 | |
| Short Term Operating Cash Flow Coverage Ratio | 26.670 | 0.533 | 0.000 | 13.927 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.283 | 0.185 | 0.220 | 0.119 | 0.152 | |
| Capital Expenditure Coverage Ratio | 33.100 | 27.218 | 2.239 | 11.486 | 22.731 | |
| Dividend Paid And Capex Coverage Ratio | 33.100 | 27.218 | 2.239 | 11.486 | 22.731 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 10.133 | 57.898 | 90.876 | -595.356 | -470.996 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 69.5% | ▼-1.3% | ▼-0.1% |
| Ebit Margin | -8.5% | ▼-0.4% | ▲0.6% |
| Ebitda Margin | 5.8% | ▲4.6% | ▲4.5% |
| Operating Profit Margin | -10.4% | ▲29.3% | ▲117.6% |
| Pretax Profit Margin | -9.3% | ▲29.4% | ▲119.3% |
| Continuous Operations Profit Margin | -7.9% | ▲31.1% | ▲120.9% |
| Net Profit Margin | -7.9% | ▲31.1% | ▲120.9% |
| Bottom Line Profit Margin | -7.9% | ▲31.1% | ▲120.9% |
| Current Ratio | 2.687 | ▲0.919 | ▼-0.296 |
| Quick Ratio | 2.592 | ▲0.865 | ▼-0.277 |
| Solvency Ratio | 0.095 | ▲0.470 | ▲1.298 |
| Cash Ratio | 1.930 | ▲0.551 | ▼-0.265 |
| Price To Earnings Ratio | -6.140 | ▼-4.592 | ▲5.349 |
| Price To Earnings Growth Ratio | 0.076 | ▲0.081 | ▼-0.107 |
| Forward Price To Earnings Growth Ratio | 0.076 | ▲0.081 | ▼-0.107 |
| Price To Earnings Diluted Ratio | -6.140 | ▼-4.592 | ▲5.396 |
| Price To Earnings Diluted Growth Ratio | 0.076 | ▲0.081 | ▼-0.108 |
| Price To Book Ratio | 0.890 | ▼-0.150 | ▼-0.307 |
| Price To Sales Ratio | 0.488 | ▼-0.116 | ▼-1.734 |
| Price To Free Cash Flow Ratio | 4.321 | ▼-1.159 | ▼-21.208 |
| Price To Operating Cash Flow Ratio | 4.191 | ▼-1.089 | ▼-18.591 |
| Debt To Assets Ratio | 0.336 | ▼-0.115 | ▲0.024 |
| Debt To Equity Ratio | 0.751 | ▼-0.312 | ▲0.098 |
| Debt To Capital Ratio | 0.429 | ▼-0.086 | ▲0.062 |
| Long Term Debt To Capital Ratio | 0.418 | ▲0.019 | ▲0.081 |
| Financial Leverage Ratio | 2.238 | ▼-0.121 | ▲0.312 |
| Working Capital Turnover Ratio | 3.602 | ▲0.732 | ▲0.732 |
| Operating Cash Flow Ratio | 0.727 | ▲0.415 | ▲0.141 |
| Operating Cash Flow Sales Ratio | 0.116 | ▲0.002 | ▲0.009 |
| Free Cash Flow Operating Cash Flow Ratio | 0.970 | ▲0.006 | ▲0.099 |
| Debt Service Coverage Ratio | 5.935 | ▲5.893 | ▲4.562 |
| Interest Coverage Ratio | -13.338 | ▲29.550 | ▲125.230 |
| Short Term Operating Cash Flow Coverage Ratio | 26.670 | ▲26.137 | ▲18.444 |
| Operating Cash Flow Coverage Ratio | 0.283 | ▲0.098 | ▲0.091 |
| Capital Expenditure Coverage Ratio | 33.100 | ▲5.882 | ▲13.745 |
| Dividend Paid And Capex Coverage Ratio | 33.100 | ▲5.882 | ▲13.745 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 10.133 | ▼-47.765 | ▲191.622 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.23B | $1.55B | $3.49B | $3.82B | $14.41B | |
| Enterprise value | $1.49B | $1.84B | $3.96B | $4.49B | $14.80B | |
| EV / Sales | 0.59x | 0.71x | 1.52x | 1.86x | 7.28x | |
| EV / Op. cash flow | 5.07x | 6.25x | 11.32x | 23.70x | 76.28x | |
| EV / Free cash flow | 5.23x | 6.49x | 20.46x | 25.97x | 79.79x | |
| EV / EBITDA | 10.13x | 57.90x | 90.88x | -595.36x | -471.00x | |
| Net debt / EBITDA | 1.76x | 9.03x | 10.74x | -88.73x | -12.31x | |
| Current ratio | 2.69x | 1.77x | 3.54x | 3.21x | 3.70x | |
| Income quality | -1.47x | -0.29x | -1.59x | -0.01x | -0.45x | |
| Graham net-net | -$4 | -$3 | -$5 | -$8 | -$4 | |
| Tax burden | 85.1% | 100.8% | 100.3% | 100.0% | 111.5% | |
| Interest burden | 109.1% | 475.9% | 104.3% | 6283.0% | 161.0% | |
| Working capital | $682.6M | $722.4M | $1.07B | $885.7M | $894.4M | |
| Invested capital | $2.32B | $2.49B | $3.89B | $3.87B | $17.38B | |
| Return on assets | -6.5% | -28.5% | -5.0% | -290.6% | -2.4% | |
| Operating ROA | -7.9% | -25.8% | -5.5% | -121.7% | -1.5% | |
| Return on tangible assets | -13.2% | -55.6% | -13.4% | -762.7% | -32.5% | |
| Return on equity | -14.5% | -67.1% | -9.5% | -591.9% | -2.7% | |
| Return on invested capital | -8.3% | -32.6% | -6.2% | -316.3% | -1.5% | |
| Return on capital employed | -9.8% | -39.6% | -6.3% | -317.4% | -1.5% | |
| Earnings yield | -16.2% | -64.6% | -6.3% | -357.7% | -3.0% | |
| Free cash flow yield | 23.1% | 18.2% | 5.5% | 4.5% | 1.3% | |
| Capex / Op. cash flow | 3.0% | 3.7% | 44.7% | 8.7% | 4.4% | |
| Capex / Depreciation | 2.4% | 2.8% | 44.8% | 6.2% | 3.9% | |
| Capex / Sales | 0.4% | 0.4% | 6.0% | 0.7% | 0.4% | |
| SG&A / Sales | 42.9% | 52.4% | 52.5% | 54.0% | 54.4% | |
| R&D / Sales | 11.0% | 12.0% | 13.4% | 13.9% | 15.3% | |
| Stock comp / Sales | 3.2% | 5.7% | 7.7% | 9.1% | 14.9% | |
| Intangibles / Total assets | 51.0% | 48.8% | 62.6% | 61.9% | 92.6% | |
| Days sales outstanding | 29d | 32d | 32d | 36d | 34d | |
| Days payables outstanding | 23d | 16d | 21d | 23d | 27d | |
| Operating cycle | 47d | 50d | 46d | 63d | 75d | |
| Cash conversion cycle | 24d | 34d | 25d | 40d | 49d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-20.4%EV / Sales ▼-17.5%EV / EBITDA ▼-82.5%EV / Op. cash flow ▼-1.183Earnings yield ▲+0.483
Profitability
Return on equity ▲+0.527Return on assets ▲+0.220Return on invested capital ▲+0.243Return on capital employed ▲+0.299Operating ROA ▲+0.179Income quality ▼-1.176Tax burden ▼-0.157
Efficiency
Days sales outstanding ▼-2.719Days payables outstanding ▲+6.595Operating cycle ▼-3.176Cash conversion cycle ▼-9.771Capex / Sales ▼-0.001R&D / Sales ▼-0.010
Balance-sheet strength
Current ratio ▲+0.919Net debt / EBITDA ▼-7.266Working capital ▼-39801000.000Invested capital ▼-177562000.000Intangibles / Total assets ▲+0.022
Change over 5 years
Valuation
Market cap ▼-91.4%EV / Sales ▼-91.9%EV / EBITDA ▲+102.2%EV / Op. cash flow ▼-71.205Earnings yield ▼-0.133
Profitability
Return on equity ▼-0.118Return on assets ▼-0.040Return on invested capital ▼-0.067Return on capital employed ▼-0.082Operating ROA ▼-0.065Income quality ▼-1.017Tax burden ▼-0.264
Efficiency
Days sales outstanding ▼-5.046Days payables outstanding ▼-3.835Operating cycle ▼-27.994Cash conversion cycle ▼-24.159Capex / Sales ▼-0.001R&D / Sales ▼-0.044
Balance-sheet strength
Current ratio ▼-1.016Net debt / EBITDA ▲+14.066Working capital ▼-211855000.000Invested capital ▼-15066953000.000Intangibles / Total assets ▼-0.416
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2023-06-26 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-01-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2021-11-26 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2021-08-18 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2021-06-21 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-11-19 | Gilbert Ray Cisneros | Purchase | $15,001 - $50,000 |
| 2020-11-17 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-10-13 | Greg Gianforte | Sale (Partial) | $1,001 - $15,000 |
| 2020-07-14 | Donald Sternoff Beyer | Sale (Full) | $15,001 - $50,000 |
| 2020-05-08 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-05-04 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-04-29 | Greg Gianforte | Sale (Partial) | $50,001 - $100,000 |
| 2020-04-27 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-04-27 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-02-14 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-01-28 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-01-09 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2019-12-23 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2018-05-04 | Brad Schneider | Purchase | $100,001 - $250,000 |
| 2017-06-04 | Brad Schneider | Purchase | $15,001 - $50,000 |
Recent news
- 2026-09-07 Here''s Why Teladoc''s Integrated Care Business Deserves More Attention TDOC''s Integrated Care is driving profitability as chronic care gains traction, potentially making it the company''s key earnings driver.
- 2026-09-03 Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08 NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued inducement awards to a new employee.
- 2026-09-02 Here''s Why Investors Should Stay Neutral on TDOC Stock for Now Teladoc Health''s growth is supported by chronic care, international expansion and Teladoc One, but BetterHelp weakness and losses temper the outlook.
- 2026-09-01 Connor Clark & Lunn Investment Management Ltd. Buys Shares of 87,511 Teladoc Health, Inc. $TDOC Connor Clark and Lunn Investment Management Ltd. bought a new position in Teladoc Health, Inc. (NYSE: TDOC) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 87,511 shares of the health services provider''s stock, valued at approximately $742,000. Several other hedge funds
- 2026-08-31 Teladoc appoints insurance executive Michael Grasher as CFO Teladoc Health said on Monday it appointed Michael Grasher as its chief financial officer, bringing in an industry veteran to help the virtual healthcare company navigate rising demand for its insurance-covered business.
- 2026-08-31 Teladoc Health Appoints Michael Grasher as Chief Financial Officer Appointment brings seasoned financial leadership as Teladoc Health advances its strategy aimed at delivering disciplined, sustainable growth NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Michael Grasher as Chief Financial Officer, effective immediately. Mr. Grasher is an accomplished financial executive with more than three decades of experience across the insurance and financial services sectors, including more than 12 years in CFO roles at public and privately held companies.
- 2026-08-28 Teladoc (TDOC) Down 3.3% Since Last Earnings Report: Can It Rebound? Teladoc (TDOC) reported earnings 30 days ago. What''s next for the stock?
- 2026-08-27 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 2026-08-25 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 2026-08-24 BetterHelp Has the Demand: Can Teladoc Build the Capacity? TDOC''s BetterHelp faces a capacity crunch as insurance demand surges, putting therapist recruitment and credentialing at the center.